news
Differences in remdesivir efficacy due to trial variances, not drug, report says
After remdesivir showed little effect against COVID-19 in the SOLIDARITY trial, a new report has suggested this is due to the structure of the study.
List view / Grid view
US National Institute of Allergy and Infectious Diseases (NIAID)
news
NIAID trial to identify potential COVID-19 treatments for further development
The adaptive ACTIV-5/BET study will test two monoclonal antibody therapies in hospitalised COVID-19 patients to establish if they warrant larger clinical trials.
news
Trial testing anti-coronavirus hIVIG plus remdesivir in COVID-19 patients
The ITAC trial will establish if adding hyperimmune intravenous immunoglobulin (hIVIG) to a remdesivir regimen can improve hospitalised COVID-19 patient outcomes.
news
COVID-19 vaccine candidate well-tolerated in older adults
The experimental COVID-19 vaccine, mRNA-1273, was well-tolerated and elicited a strong immune response in older adults during a Phase I trial.
news
Phase III trial of J&J COVID-19 vaccine candidate enrols first volunteers
A Phase III clinical trial to evaluate J&J's COVID-19 vaccine in multiple countries has enrolled its first patients.
news
Baricitinib and remdesivir reduce time to recovery in COVID-19 patient trial
A study of baricitinib in combination with remdesivir has met its primary endpoint in COVID-19 patients, by reducing time to recovery in comparison with only remdesivir.
news
Phase III testing of AstraZeneca’s AZD1222 vaccine has begun in the US
The clinical study will evaluate the efficacy of AZD1222, a COVID-19 vaccine candidate, in preventing symptomatic COVID-19 at 80 sites across the US.
news
Two Phase III trials in US to evaluate efficacy of mAbs against COVID-19
Two randomised Phase III clinical trials to test mAbs against COVID-19 are now enrolling healthy adults in the US, the NIH has announced.
news
Moderna initiates Phase III trial of COVID-19 vaccine candidate
The first patients have been dosed in Moderna's Phase III clinical trial of its mRNA vaccine candidate to protect against COVID-19.
news
Phase III COVID-19 antibody trials initiated in Americas
Simultaneous Phase III trials evaluating Regeneron’s REGN-COV2 antibody as both a prophylactic and a treatment have begun in US and some South American locations.
news
EMA recommends authorisation for remdesivir to combat COVID-19
The EMA's human medicines committee (CHMP) has recommended a conditional marketing authorisation for Veklury (remdesivir) to treat COVID-19.
news
Lilly launches Phase I trial of investigational COVID-19 antibody treatment
The enterprise announced the initiation of the LY-CoV555 COVID-19 antibody treatment trial at medical centres across the US.
news
Phase IIb trial to study hydroxychloroquine and azithromycin as COVID-19 treatment launched
A double-blind clinical trial has begun in the US to study hydroxychloroquine and azithromycin treatment in patients with COVID-19.
news
FDA grants Fast Track Designation to Moderna’s COVID-19 vaccine
The US FDA has given Fast Track Designation to Moderna's mRNA vaccine candidate, mRNA-1273, designed to protect against COVID-19.
article
COVID-19: the big repurpose and even bigger pharmaceutical partnership
Heidi West discusses how academia, government and the pharmaceutical industry can work together to potentially repurpose drugs for the treatment of COVID-19.
